Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma
TD-NICE study was registered in the August 28, 2020, and the registration number was ChiCTR2000037488 (Chinese Clinical Trial Registry (ChiCTR) identifier).
Authors
- Hongtao Duan (ORCID: https://orcid.org/0000-0002-1985-2292)
- Changjian Shao (ORCID: https://orcid.org/0000-0002-2487-9692)
- Yajie Mao
- Yi-Chen Sun (ORCID: https://orcid.org/0000-0002-3247-0774)
- Xiaolong Yan (ORCID: https://orcid.org/0000-0003-2419-9707)
- Zhiyuan Gao
Institutions
- Air Force Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1186/s12885-025-14686-9
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shaanxi Science and Technology Co-ordination and Innovation Project of China